Insights
Search Results
Client Highlights
2.06.26
Wilson Sonsini Advises PacBio on Sale of Short-Read DNA Sequencing Assets
On February 2, 2026, PacBio, a leading developer of high-quality, highly accurate sequencing solutions, announced the completion of the sale of select intellectual property and other assets related to PacBio’s short-read DNA sequencing technology and related clustering, sequencing reagent, and detection technologies to Illumina, Inc. PacBio received approximately $50 million in cash proceeds from the transaction. Wilson Sonsini Goodrich & Rosati advised PacBio on the transaction.
Client Highlights
11.10.25
Wilson Sonsini Advises Iambic on Oversubscribed $100 Million Financing
On November 10, 2025, Iambic, a clinical-stage life science and technology company developing novel medicines using its AI-driven discovery and development platform, announced that it has raised approximately $100 million in an oversubscribed financing round. Wilson Sonsini Goodrich & Rosati advised Iambic on the transaction.
Client Highlights
11.08.24
Wilson Sonsini Advises PacBio on $459 Million Convertible Note Exchange
On November 7, 2024, Pacific Biosciences of California, Inc. (PacBio), a leading developer of high-quality, highly accurate sequencing solutions, announced that it entered into a privately negotiated exchange agreement with a holder of PacBio’s remaining outstanding 1.50 percent convertible senior notes due 2028, pursuant to which PacBio will (i) issue $200 million principal amount of its 1.50 percent Convertible Senior Notes due 2029, (ii) issue 20,451,570 shares of PacBio’s common stock, and (iii) make a cash payment in the amount of $50 million in exchange for $459 million principal amount of the 2028 Notes. The exchange transaction is expected to close on or about November 21, 2024, subject to customary closing conditions.
Client Highlights
6.18.24
Wilson Sonsini Advises Iambic Therapeutics on $50 Million Series B Extension, Bringing Total Series B Funding to Over $150 Million
On June 18, 2024, Iambic Therapeutics (Iambic), a clinical-stage biotechnology company developing novel therapeutics from its unique generative AI discovery platform, announced the closing of an oversubscribed $50 million extension, bringing the total Series B funding to over $150 million. The Series B extension was led by new investors Mubadala Capital and Exor Ventures, and existing investors Abingworth, Illumina Ventures, Nexus Venture Partners, Coatue, and Tao Capital Partners. Wilson Sonsini Goodrich & Rosati advised Iambic on the transaction.
News Articles
10.16.23
SDBJ Names Karen Deschaine and Zachary Myers Among 2023 “Top 100 Leaders in Law”
On October 16, 2023, The San Diego Business Journal released its 2023 “Top 100 Leaders in Law” honorees, which included the recognition of Wilson Sonsini partners Karen Deschaine and Zachary Myers and an accompanying feature that highlights the careers of both attorneys.
Client Highlights
10.03.23
Firm Advises Iambic Therapeutics on $100 Million Series B Financing
On October 3, 2023, Iambic Therapeutics, a biotechnology company developing novel therapeutics from its unique generative AI discovery platform, announced the closing of an oversubscribed $100 million Series B financing. The financing was co-led by Ascenta Capital and Abingworth, and included new investors NVIDIA and Illumina Ventures. Existing investors also participated, including Nexus Ventures, Catalio Capital Management, Coatue, FreeFlow, OrbiMed, and Sequoia Capital. Wilson Sonsini Goodrich & Rosati advised Iambic on the transaction.
Client Highlights
8.03.23
Wilson Sonsini Advises PacBio on Apton Biosystems Acquisition
On August 2, 2023, Pacific Biosciences of California (PacBio), a leading provider of high-quality, long-read sequencing platforms, announced that it has signed a definitive merger agreement to acquire Apton Biosystems, Inc. (Apton), a Bay-Area-based company developing a high throughput short-read sequencer using state-of-the-art optics and image processing, paired with novel clustering and chemistry, that is designed to enable the sequencing of billions of clusters of DNA on one flow cell. Wilson Sonsini Goodrich & Rosati is representing PacBio in the transaction.
Client Highlights
6.26.23
Wilson Sonsini Advises PacBio on $441 Million Senior Notes Offering
On June 26, 2023, Pacific Biosciences of California, Inc. (PacBio) announced that it has entered into a privately negotiated exchange agreement with a holder of PacBio's outstanding 1.50 percent convertible senior notes due 2028, pursuant to which PacBio will issue $441 million principal amount of its 1.375 percent convertible senior notes due 2030 in exchange for $441 million principal amount of the 2028 notes (the Exchange Transaction), in a transaction exempt from registration under the Securities Act of 1933, as amended, and the rules and regulations thereunder. The Exchange Transaction is expected to close on or about June 30, 2023, subject to customary closing conditions.
Client Highlights
1.26.23
Firm Advises Pacific Biosciences of California on Upsized Stock Offering
On January 24, 2023, life sciences technology company Pacific Biosciences of California Inc announced that it has priced a 17.5 million share secondary stock offering at $10 per share. The transaction will raise $175 million, which was upsized from the original size of $150 million. Wilson Sonsini Goodrich & Rosati advised Pacific Biosciences on the transaction.
Client Highlights
3.15.22
Wilson Sonsini Advises Nalu Medical on $104 Million Equity Financing
On February 17, 2022, Nalu Medical, Inc., a private company focused on innovative and minimally invasive solutions for chronic neuropathic pain, announced a $104 million equity financing. The round was led by new investors MVM Partners and Gilde Healthcare. New investors Pura Vida Investments and Aperture Venture Partners, as well as existing investors Advent Life Sciences, Decheng Capital, Endeavour Vision, and Longitude Capital, also participated in the round. The proceeds from this financing are intended to be used for scaling commercial operations to accelerate growth, continued expansion of clinical evidence, and continuing product development, in addition to other general corporate purposes. Wilson Sonsini Goodrich & Rosati advised Nalu Medical on the transaction.
Client Highlights
2.07.22
Wilson Sonsini Advises 1859, Inc. on Launch and $40 Million Series A
On February 7, 2022, 1859, Inc., a platform company combining artificial intelligence and empirical pico-scale screening data at scale to discover new small molecule medicines for emerging disease targets, launched and announced the close of a $40 million Series A funding round led by Northpond Ventures and OMX Ventures. Existing investors FusionX Ventures and Vertical Venture Partners also joined the round. Wilson Sonsini Goodrich & Rosati advised 1859 on corporate and IP matters related to the company’s launch and financing.
Client Highlights
6.11.21
Wilson Sonsini Represents Nautilus Biotechnology in $345 Million Business Combination with Arya Sciences Acquisition Corp III; NAUT Begins Trading on Nasdaq Global Select Market
On June 9, 2021, Nautilus Biotechnology, a company pioneering a single-molecule protein analysis platform for quantifying the proteome, announced the completion of its business combination with Arya Sciences Acquisition Corp III, a special purpose acquisition company (SPAC) sponsored by Perceptive Advisors. The combined company, Nautilus Biotechnology, began trading shares of its common stock under the ticker symbol "NAUT" on the Nasdaq Global Select Market on June 10, 2021. The business combination was approved by Arya III’s shareholders on June 8, 2021. Gross proceeds from this transaction totaled approximately $345 million, which included approximately $145 million of funds held in Arya III’s trust account and the concurrent common stock private investment in public equity (PIPE) financing of $200 million led by Perceptive Advisors, an affiliate of Arya III’s sponsor, as well as RA Capital Management, Ally Bridge Group, Bain Capital Life Sciences, Franklin Templeton Investments, OrbiMed, Alyeska Investment Group, L.P., Casdin Capital, and existing Nautilus Biotechnology shareholders including Andreessen Horowitz, Madrona Venture Group, and Vulcan Capital.